Topic hub

Injury recovery

Tendons are notoriously bad at healing. The blood supply is poor, the cell turnover is slow, and most interventions — physiotherapy, NSAIDs, corticosteroids — treat the symptom rather than the mechanism. BPC-157 and TB-500 work differently, at least in the animal data. They promote angiogenesis, accelerate collagen synthesis, and reduce inflammatory markers in ways that look mechanistically interesting. The human evidence is thinner — small series, case reports, no randomised trials yet. That's the honest picture. This hub covers the research as it stands, not as we'd like it to be.

Join the waitlist

State of the evidence

BPC-157 and TB-500 dominate the injury-recovery literature, and the animal data is genuinely striking — faster tendon healing, accelerated angiogenesis, reduced inflammation markers. The human evidence is sparse: case reports, small series, no randomised controlled trials in this indication. What the corpus does show is a consistent mechanistic picture across multiple injury models. That's meaningful signal. It's also not the same thing as a clinical proof of efficacy.

Signal snapshot: 2026-05-21

How peptides influence collagen synthesis: the mechanism behind the claims

WADA

Three peptides under FDA review have animal-model evidence touching collagen biology — BPC-157, GHK-Cu, and TB-500. The mechanism story varies per peptide. The human evidence does not. Here is what collagen is and where the prescribing files diverge.

Angiogenesis and peptide therapy: what new blood-vessel growth has to do with recovery

WADA

Two peptides on the July 2026 FDA review docket — BPC-157 and TB-500 — rest their entire animal mechanism story on the same biology: new blood-vessel growth into damaged tissue. Here is what that means, where the human evidence sits, and the open question angiogenesis always raises.

BPC-157 vs GHK-Cu for tissue repair: different pathways, overlapping results

WADA

BPC-157 and GHK-Cu both get sold as tissue-repair peptides. They share almost nothing else — different parent molecules, different anatomical evidence, and only one of them is on the FDA's July 2026 review docket. Here is what the published data actually separates them on.

BPC-157 vs TB-500 for injury recovery: what the evidence actually separates

WADA

BPC-157 and TB-500 get sold side-by-side as the injury-recovery peptide stack. Two different proteins, two different evidence bases, two different gaps. Here is what the published data actually says — and where the July 2026 FDA review treats them as one regulatory question.

TB-500 and tendon repair: what the research actually says about the protein your tendons were already making

WADA

TB-500 has a reputation for pulling tendons back from chronic pain. The underlying protein is real. The tendon-specific evidence is thinner than the forums imply. Here is what the research actually shows, what nobody has tested in a human tendon, and how the July 2026 FDA review fits.

KPV: Anti-Inflammatory Peptide Research and the PCAC July 2026 Docket

Science-journalism overview of KPV — the alpha-MSH tripeptide fragment studied for gut inflammation and wound healing, its evidence base, and its position on the PCAC July 23–24 2026 review agenda.

TB-500 / Thymosin Beta-4: Tissue Repair Research and Regulatory Overview

WADA

Science-journalism overview of TB-500 (Thymosin Beta-4) research — what animal and limited human data suggest about tissue repair, and where the compound stands under PCAC July 2026 review.

BPC-157 and injury recovery: what the animal studies actually show

WADA

BPC-157 has a reputation for rebuilding tendons and joints. Almost all of that reputation rests on animal studies. Here is what the injury-recovery evidence actually says, where the human gap sits, and why the July 2026 FDA review matters.